Aim immunotech announces abstract accepted for poster presentation at the british society for immunology congress 2022

Ocala, fla., dec. 02, 2022 (globe newswire) --  aim immunotech inc. (nyse american: aim) (“aim” or the “company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including covid-19, the disease caused by the sars-cov-2 virus, today announced its abstract has been accepted for poster presentation at the british society for immunology congress 2022 being held december 5-8, 2022 in liverpool, uk.
AIM Ratings Summary
AIM Quant Ranking